StockNews.AI
MDAI
StockNews.AI
15 mins

Spectral AI Named to TIME's List of World's Top HealthTech Companies 2025

1. MDAI named in TIME's Top HealthTech Companies 2025 list. 2. Recognition highlights Spectral AI's progress in medical diagnostics. 3. DeepView technology aims to improve wound care treatment decisions. 4. List evaluated companies on performance and online engagement metrics. 5. MDAI's innovation expected to improve healthcare outcomes and reduce costs.

5m saved
Insight
Article

FAQ

Why Bullish?

Being listed in a prestigious ranking boosts MDAI's reputation and investor confidence. Past recognition in industry rankings often leads to positive stock performance.

How important is it?

Recognition in the HealthTech sector enhances brand visibility and potential market adoption for MDAI's technology, making it integral for future success.

Why Long Term?

While immediate impacts may be muted, sustained recognition can drive long-term growth and commercialization opportunities, similar to previous tech health companies gaining market traction.

Related Companies

NVDAPTONADBE
DALLAS, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been named to TIME’s World’s Top HealthTech Companies 2025 list. The ranking, released September 18, 2025, can be viewed on Time.com. The list, compiled by TIME and Statista Inc., recognizes leading innovators advancing healthcare globally through technology. Companies were evaluated on financial performance, reputation analysis, and online engagement. Out of thousands of HealthTech companies reviewed, 400 were recognized for their outstanding performance across these categories. J. Michael DiMaio, M.D., Chairman of Spectral AI, said, “Being named to TIME’s World’s Top HealthTech Companies 2025 list alongside so many great companies is a huge milestone for Spectral AI and our DeepView technology. This recognition underscores the progress our team has made as we work toward global commercialization. Every team member continues to strive to deliver our innovative AI-based predictive wound care technology to the medical community.” About Spectral AISpectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView System, visit www.spectral-ai.com. Forward-Looking StatementsCertain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside of the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.  Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.  For Media and Investor Relations, please contact: David KugelmanAtlanta Capital Partners LLC(866) 692-6847 Toll Free - U.S. & Canada(404) 281-8556 Mobile and WhatsAppEmail: dk@atlcp.com

Related News